BioGentech Corp. Confirms Successful Termination of Its Unauthorized Listing on Berlin-Bremen Stock Exchange IRVINE, Calif., May 26, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a publicly held Nevada corporation dedicated to developing and commercializing over-the-counter (OTC) products for the...

BioGentech Announces ClinDatrix as CRO for Phase III Trials IRVINE, Calif., April 29, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today that it has entered...

BioGentech Finalizes Outsourcing Partnerships for Prehistin Phase III Clinical Trials IRVINE, Calif., March 31, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today the finalization of...

BioGentech Receives FDA Approval to Begin Phase III Clinical Trials IRVINE, Calif., March 26, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced today the Division of...

BioGentech Appoints Chairman and Additional Board Member IRVINE, Calif., March 26, 2004 (PRIMEZONE) -- BioGentech Corp. (OTCBB:BGTH), a pharmaceutical company specializing in over-the-counter anti-allergic medications, announced today that its Board of...